Design and Molecular Dynamics Simulation of Peptide Inhibitors Targeting Amyloid-Beta Aggregation
DOI:
https://doi.org/10.5281/zenodo.22638201Keywords:
amyloid-beta, peptide inhibitor, molecular dynamics simulation, Alzheimer's disease, aggregation inhibitionAbstract
Background: Aggregation of amyloid-beta (Abeta) into oligomers and fibrils is central to Alzheimer's disease pathogenesis, and
peptide-based ligands remain among the most structurally precise tools for blocking this process. Objective: To synthesise
published literature on rationally designed and computationally identified peptide inhibitors of Abeta aggregation and the
molecular dynamics (MD) studies that explain their mechanisms. Methods: Narrative review of peptide-inhibitor design and MD
simulation studies targeting Abeta aggregation, identified via PubMed, Google Scholar, Crossref and bioRxiv. Findings:
Recognition-sequence peptides (KLVFF), beta-sheet breakers (LPFFD), N-methylated and D-enantiomeric peptides, molecular
tweezers (CLR01) and cell-penetrating designs each interfere with the central hydrophobic core or C-terminal self-recognition
motifs; MD and steered-MD studies, informed by solid-state NMR and cryo-EM fibril structures, converge on disruption of
in-register beta-sheet stacking and salt-bridge networks as a shared mechanism. Conclusions: Peptide inhibitors targeting defined
Abeta interfaces are mechanistically well characterised, but proteolytic instability and blood-brain barrier penetration remain the
principal translational barriers.
References
Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184-185. doi:10.1126/science.1566067
Walsh DM, Selkoe DJ. Abeta oligomers - a decade of discovery. J Neurochem. 2007;101(5):1172-1184. doi:10.1111/j.1471-4159.2006.04426.x
Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333-366. doi:10.1146/annurev.biochem.75.101304.123901
Nasica-Labouze J, Nguyen PH, Sterpone F, Berthoumieu O, Buchete NV, Côté S, De Simone A, Doig AJ, Faller P, Garcia A, Laio A, Li MS, Melchionna S, Mousseau N, Mu Y, Paravastu A, Pasquali S, Rosenman DJ, Strodel B, Tarus B, Viles JH, Zhang T, Wang C, Derreumaux P. Amyloid β protein and Alzheimer's disease: when computer simulations complement experimental studies. Chem Rev. 2015;115(9):3518-3563. doi:10.1021/cr500638n
Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Schubert D, Riek R. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A. 2005;102(48):17342-17347. doi:10.1073/pnas.0506723102
Colvin MT, Silvers R, Ni QZ, Can TV, Sergeyev I, Rosay M, Donovan KJ, Michael B, Wall J, Linse S, Griffin RG. Atomic resolution structure of monomorphic Aβ42 amyloid fibrils. J Am Chem Soc. 2016;138(30):9663-9674. doi:10.1021/jacs.6b05129
Wälti MA, Ravotti F, Arai H, Glabe CG, Wall JS, Böckmann A, Güntert P, Meier BH, Riek R. Atomic-resolution structure of a disease-relevant Aβ(1-42) amyloid fibril. Proc Natl Acad Sci U S A. 2016;113(34):E4976-E4984. doi:10.1073/pnas.1600749113
Gremer L, Schölzel D, Schenk C, Reinartz E, Labahn J, Ravelli RBG, Tusche M, Lopez-Iglesias C, Hoyer W, Heise H, Willbold D, Schröder GF. Fibril structure of amyloid-β(1-42) by cryo-electron microscopy. Science. 2017;358(6359):116-119. doi:10.1126/science.aao2825
Tjernberg LO, Näslund J, Lindqvist F, Johansson J, Karlström AR, Thyberg J, Terenius L, Nordstedt C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996;271(15):8545-8548. doi:10.1074/jbc.271.15.8545
Lowe TL, Strzelec A, Kiessling LL, Murphy RM. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry. 2001;40(26):7882-7889. doi:10.1021/bi002734u
Jokar S, Khazaei S, Behnammanesh H, Shamloo A, Erfani M, Beiki D, Bavi O. Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer's disease therapy. Biophys Rev. 2019;11(6):901-925. doi:10.1007/s12551-019-00606-2
Soto C, Sigurdsson EM, Morelli L, Kumar RA, Castaño EM, Frangione B. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998;4(7):822-826. doi:10.1038/nm0798-822
Kokkoni N, Stott K, Amijee H, Mason JM, Doig AJ. N-methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry. 2006;45(32):9906-9918. doi:10.1021/bi060837s
Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E, Schmitt B, Bucci E, Willbold D. Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide Abeta1-42 by mirror image phage display. ChemBioChem. 2003;4(8):748-753. doi:10.1002/cbic.200300631
Funke SA, van Groen T, Kadish I, Bartnik D, Nagel-Steger L, Brener O, Sehl T, Batra-Safferling R, Moriscot C, Schoehn G, Horn AH, Muller-Schiffmann A, Korth C, Sticht H, Willbold D. Oral treatment with the D-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice. ACS Chem Neurosci. 2010;1(9):639-648. doi:10.1021/cn100057j
Klein AN, Ziehm T, Tusche M, Buitenhuis J, Bartnik D, Boeddrich A, Wiglenda T, Wanker E, Funke SA, Brener O, Gremer L, Kutzsche J, Willbold D. Optimization of the all-D peptide D3 for Aβ oligomer elimination. PLoS One. 2016;11(4):e0153035. doi:10.1371/journal.pone.0153035
Mehrazma B, Opare S, Petoyan A, Rauk A. D-amino acid pseudopeptides as potential amyloid-beta aggregation inhibitors. Molecules. 2018;23(9):2387. doi:10.3390/molecules23092387
Lu J, Cao Q, Wang C, Zheng J, Luo F, Xie J, Li Y, Ma X, He L, Eisenberg D, Nowick J, Jiang L, Li D. Structure-based peptide inhibitor design of amyloid-β aggregation. Front Mol Neurosci. 2019;12:54. doi:10.3389/fnmol.2019.00054
Horsley JR, Jovcevski B, Wegener KL, Yu J, Pukala TL, Abell AD. Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease. Biochem J. 2020;477(11):2039-2054. doi:10.1042/bcj20200290
Henning-Knechtel A, Kumar S, Wallin C, Król S, Wärmländer SKTS, Jarvet J, Esposito G, Kirmizialtin S, Gräslund A, Hamilton AD, Magzoub M. Designed cell-penetrating peptide inhibitors of amyloid-beta aggregation and cytotoxicity. Cell Rep Phys Sci. 2020;1(2):100014. doi:10.1016/j.xcrp.2020.100014
Eskici G, Gur M. Computational design of new peptide inhibitors for amyloid beta (Aβ) aggregation in Alzheimer's disease: application of a novel methodology. PLoS One. 2013;8(6):e66178. doi:10.1371/journal.pone.0066178
Qiao Y, Zhang M, Liang Y, Zheng J, Liang G. A computational study of self-assembled hexapeptide inhibitors against amyloid-β (Aβ) aggregation. Phys Chem Chem Phys. 2017;19(1):155-166. doi:10.1039/c6cp07341g
Sinha S, Lopes DHJ, Du Z, Pang ES, Shanmugam A, Lomakin A, Talbiersky P, Tennstaedt A, McDaniel K, Bakshi R, Kuo PY, Ehrmann M, Benedek GB, Loo JA, Klärner FG, Schrader T, Wang C, Bitan G. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc. 2011;133(42):16958-16969. doi:10.1021/ja206279b
Huang Q, Zhao Q, Peng J, Yu Y, Wang C, Zou Y, Su Y, Zhu L, Wang C, Yang Y. Peptide-polyphenol (KLVFF/EGCG) binary modulators for inhibiting aggregation and neurotoxicity of amyloid-β peptide. ACS Omega. 2019;4(2):4233-4242. doi:10.1021/acsomega.8b02797
Nguyen PH, Derreumaux P. Understanding amyloid fibril nucleation and Aβ oligomer/drug interactions from computer simulations. Acc Chem Res. 2014;47(2):603-611. doi:10.1021/ar4002075
Cobos-Montes K, Fuentes SE, Estuardo F, Cárdenas C, Guzmán F, Santana P, Gavilán J, Figueroa M, Fuentealba J, Jiménez VA, Ramírez D. Molecular mechanism of beta-amyloid aggregation inhibition by KLVFF. J Chem Inf Model. 2026;66(1):684-700. doi:10.1021/acs.jcim.5c01967
Sehra N, Parmar R, Jain R. Peptide-based amyloid-beta aggregation inhibitors. RSC Med Chem. 2025;16(3):1083-1104. doi:10.1039/d4md00729h
Al Khzem AH, Gomaa MS. Peptide-based therapeutics for Alzheimer's disease: medicinal chemistry, AI-guided computational design, and blood-brain barrier delivery. Drug Des Devel Ther. 2026;20:1-28. doi:10.2147/dddt.s597087
